Retinopathy linked with cardiovascular disease

Article

Diabetic retinopathy (DR), particularly in the more advanced stages, is associated with an increased cardiovascular disease (CVD) incidence.

Diabetic retinopathy (DR), particularly in the more advanced stages, is associated with an increased cardiovascular disease (CVD) incidence, according to the results of a study published in the January issue of Diabetic Medicine.

Giovanni Targher and co-workers from the Hospital of Negrar and the University Hospital of Verona, Italy investigated the association between DR and the risk of incident CVD in 2,103 Type 2 diabetic outpatients who were free from CVD at baseline. Retinal findings were classified based on fundoscopy to categories of no retinopathy, non-proliferative retinopathy and proliferative/laser-treated retinopathy.

During the seven-year follow-up period, 406 subjects developed incident CVD events. Following adjustment for age, body mass index, waist circumference, smoking, lipids, glycated haemoglobin, diabetes duration and medication use, patients with non-proliferative or proliferative/laser-treated retinopathy had a greater risk (p<0.001) of incident CVD events than those without retinopathy.

After additional adjustments for hypertension and advanced nephropathy, the risk of incident CVD markedly increased in those with proliferative/laser-treated retinopathy but not in those with non-proliferative retinopathy.

It was concluded that DR is associated with an increased CVD incidence.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.